ADVB
Advanced Biomed, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.30
−12.88%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 127.6K | 127.6K | — | — | — |
| Cost of Revenue | 5.0M | 6.4M | — | — | — |
| Gross Profit | (4.9M) | (6.2M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 665.5K | — | 909.8K | 880.2K | 1.4M |
| SG&A Expense | 747.5K | — | 2.1M | 1.7M | 1.7M |
| General & Admin Expense | 747.5K | — | 2.1M | 1.7M | 1.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 27.3K | — | — | — | — |
| Total Operating Expenses | 1.4M | — | 3.0M | 2.5M | 3.1M |
| Cost and Expenses | 6.5M | 6.4M | 3.0M | 2.5M | 3.1M |
| Operating Income (EBIT) | (6.4M) | (6.2M) | (3.0M) | (2.5M) | (3.1M) |
| Non-Operating | |||||
| Interest Income | 9.7K | — | 24.9K | 53.5K | 21.4K |
| Interest Expense | 7.1K | 7.0K | — | — | — |
| Net Interest Income | 2.5K | (7.0K) | 24.9K | 53.5K | 21.4K |
| Other Non-Op Income/Expense | (28.1K) | (28.9K) | (237.9K) | (240.7K) | (661.6K) |
| Non-Operating Income (excl Interest) | 158.0K | 21.9K | 237.9K | 240.7K | 661.6K |
| EBT (Pre-Tax Income) | (6.4M) | (6.3M) | (3.3M) | (2.8M) | (3.7M) |
| Income Tax Expense | (1.2K) | (1.2K) | — | — | — |
| Bottom Line | |||||
| Net Income | 6.7M | 6.7M | (3.3M) | (2.8M) | (3.7M) |
| Earnings from Cont. Ops | (6.4M) | (6.3M) | (3.3M) | (2.8M) | (3.7M) |
| Earnings from Discont. Ops | 13.1M | 12.9M | — | — | — |
| Bottom Line Net Income | 6.7M | 6.7M | (3.3M) | (2.8M) | (3.7M) |
| Per Share | |||||
| Basic EPS | $0.47 | $5.33 | ($0.16) | ($0.14) | ($0.19) |
| Diluted EPS | $0.47 | $5.33 | ($0.16) | ($0.14) | ($0.19) |
| Revenue Per Share | $0.10 | $0.10 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.3M | 1.3M | 20.5M | 20.0M | 19.9M |
| Diluted Shares Outstanding | 1.3M | 1.3M | 20.5M | 20.0M | 19.9M |
| Profitability Metrics | |||||
| EBITDA | (6.4M) | (6.3M) | (2.9M) | (2.4M) | (3.4M) |
| D&A | 71.8K | — | 343.8K | 399.6K | 365.2K |
| EBIT | (6.5M) | (6.3M) | (3.3M) | (2.8M) | (3.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026